These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 27602501

  • 21. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
    Daley BR, Vieira HM, Rao C, Hughes JM, Beckley ZM, Huisman DH, Chatterjee D, Sealover NE, Cox K, Askew JW, Svoboda RA, Fisher KW, Lewis RE, Kortum RL.
    Proc Natl Acad Sci U S A; 2023 Nov 21; 120(47):e2313137120. PubMed ID: 37972068
    [Abstract] [Full Text] [Related]

  • 22. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN, Lou SY, Lu J, Zheng FL, Tang YM, Zhang EJ, Cui SL, Zhao HJ.
    Cell Death Dis; 2024 Jul 03; 15(7):474. PubMed ID: 38956060
    [Abstract] [Full Text] [Related]

  • 23. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.
    Cancer Res; 2013 Jul 01; 73(13):4075-85. PubMed ID: 23633485
    [Abstract] [Full Text] [Related]

  • 24. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q, Sun X, Guo H, Yu Q.
    Oncotarget; 2017 Jan 17; 8(3):5003-5015. PubMed ID: 28002807
    [Abstract] [Full Text] [Related]

  • 25. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR, Thomas P, Loggie BW, Govindarajan V.
    PLoS One; 2017 Jan 17; 12(6):e0179510. PubMed ID: 28640835
    [Abstract] [Full Text] [Related]

  • 26. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC, Qian Y, Li X, Xu J, Kang W, Tong JH, To KF, Jin Y, Li W, Chen H, Go MY, Wu JL, Cheng KW, Ng SS, Sung JJ, Cai Z, Yu J.
    Gastroenterology; 2016 Nov 17; 151(5):945-960.e6. PubMed ID: 27451147
    [Abstract] [Full Text] [Related]

  • 27. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
    Alves S, Castro L, Fernandes MS, Francisco R, Castro P, Priault M, Chaves SR, Moyer MP, Oliveira C, Seruca R, Côrte-Real M, Sousa MJ, Preto A.
    Oncotarget; 2015 Oct 13; 6(31):30787-802. PubMed ID: 26418750
    [Abstract] [Full Text] [Related]

  • 28. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
    Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P, GERMAN NET-Z study group.
    PLoS One; 2017 Oct 13; 12(8):e0182852. PubMed ID: 28800359
    [Abstract] [Full Text] [Related]

  • 29. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
    Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.
    World J Gastroenterol; 2019 Feb 21; 25(7):808-823. PubMed ID: 30809081
    [Abstract] [Full Text] [Related]

  • 30. Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA.
    Yousef AI, El-Masry OS, Abdel Mohsen MA.
    Asian Pac J Cancer Prev; 2016 Feb 21; 17(2):743-8. PubMed ID: 26925673
    [Abstract] [Full Text] [Related]

  • 31. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, Song SH, Kim SJ, Han SW, Park KJ, Kim TY.
    Int J Cancer; 2019 Jan 15; 144(2):389-401. PubMed ID: 29978469
    [Abstract] [Full Text] [Related]

  • 32. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A, Lai C, McDonald S, Suraweera N, Sengupta N, Propper D, Dorudi S, Silver A.
    Exp Mol Pathol; 2013 Feb 15; 94(1):103-8. PubMed ID: 22982087
    [Abstract] [Full Text] [Related]

  • 33. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E.
    J Exp Clin Cancer Res; 2019 Jan 28; 38(1):41. PubMed ID: 30691487
    [Abstract] [Full Text] [Related]

  • 34. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
    Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM.
    Ann Surg; 2006 Jun 28; 243(6):833-42; discussion 843-4. PubMed ID: 16772787
    [Abstract] [Full Text] [Related]

  • 35. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S, Hong M, Shin MK, Kim BC, Shin HS, Yu E, Hong SM, Kim J, Chun SM, Kim TI, Choi KC, Ko YW, Kim JW.
    Hum Pathol; 2017 Jul 28; 65():21-30. PubMed ID: 28188750
    [Abstract] [Full Text] [Related]

  • 36. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS.
    PLoS One; 2016 Jul 28; 11(3):e0151865. PubMed ID: 26991109
    [Abstract] [Full Text] [Related]

  • 37. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.
    Clin Cancer Res; 2015 Dec 15; 21(24):5499-5510. PubMed ID: 26272063
    [Abstract] [Full Text] [Related]

  • 38. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells.
    Park J, Jang JH, Kim JH.
    Biochim Biophys Acta Mol Cell Res; 2019 Mar 15; 1866(3):329-336. PubMed ID: 30553812
    [Abstract] [Full Text] [Related]

  • 39. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I, Ozkan AC, Ekmekci A.
    Tumour Biol; 2015 Dec 15; 36(12):9339-45. PubMed ID: 26108998
    [Abstract] [Full Text] [Related]

  • 40. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
    Anderson GR, Winter PS, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Ali M, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, Wood KC.
    Cell Rep; 2017 Jul 25; 20(4):999-1015. PubMed ID: 28746882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.